A newly developed canine soft tissue sarcoma cell line, FACC-19CSTS36, with a Sanger sequence confirmed COL3A1-PDGFB fusion was tested for sensitivity to imatinib, a tyrosine kinase inhibitor capable of inhibiting v-Abl, c-Kit, and PDGFR. This evidence concerns the gene KIT and soft tissue sarcoma.